Forte Biosciences (FBRX) Competitors $10.55 -0.90 (-7.86%) Closing price 04:00 PM EasternExtended Trading$10.68 +0.13 (+1.18%) As of 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FBRX vs. CTOR, OLMA, AURA, ATXS, ZYBT, LFCR, BNTC, AVIR, IVA, and AARDShould you be buying Forte Biosciences stock or one of its competitors? The main competitors of Forte Biosciences include Citius Oncology (CTOR), Olema Pharmaceuticals (OLMA), Aura Biosciences (AURA), Astria Therapeutics (ATXS), Zhengye Biotechnology (ZYBT), Lifecore Biomedical (LFCR), Benitec Biopharma (BNTC), Atea Pharmaceuticals (AVIR), Inventiva (IVA), and Aardvark Therapeutics (AARD). These companies are all part of the "pharmaceutical products" industry. Forte Biosciences vs. Its Competitors Citius Oncology Olema Pharmaceuticals Aura Biosciences Astria Therapeutics Zhengye Biotechnology Lifecore Biomedical Benitec Biopharma Atea Pharmaceuticals Inventiva Aardvark Therapeutics Forte Biosciences (NASDAQ:FBRX) and Citius Oncology (NASDAQ:CTOR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations. Do institutionals and insiders have more ownership in FBRX or CTOR? 77.6% of Forte Biosciences shares are held by institutional investors. Comparatively, 70.5% of Citius Oncology shares are held by institutional investors. 5.9% of Forte Biosciences shares are held by company insiders. Comparatively, 4.6% of Citius Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts rate FBRX or CTOR? Forte Biosciences currently has a consensus target price of $61.00, suggesting a potential upside of 478.20%. Citius Oncology has a consensus target price of $3.00, suggesting a potential upside of 6.38%. Given Forte Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Forte Biosciences is more favorable than Citius Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Forte Biosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Citius Oncology 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has better valuation and earnings, FBRX or CTOR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioForte BiosciencesN/AN/A-$35.48M-$16.29-0.65Citius OncologyN/AN/AN/AN/AN/A Is FBRX or CTOR more profitable? Citius Oncology's return on equity of -53.88% beat Forte Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Forte BiosciencesN/A -149.15% -114.25% Citius Oncology N/A -53.88%-18.86% Which has more volatility and risk, FBRX or CTOR? Forte Biosciences has a beta of 2.97, indicating that its share price is 197% more volatile than the S&P 500. Comparatively, Citius Oncology has a beta of 3.06, indicating that its share price is 206% more volatile than the S&P 500. Does the media prefer FBRX or CTOR? In the previous week, Citius Oncology had 1 more articles in the media than Forte Biosciences. MarketBeat recorded 4 mentions for Citius Oncology and 3 mentions for Forte Biosciences. Forte Biosciences' average media sentiment score of 1.29 beat Citius Oncology's score of 0.66 indicating that Forte Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Forte Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Citius Oncology 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryForte Biosciences beats Citius Oncology on 6 of the 10 factors compared between the two stocks. Get Forte Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for FBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FBRX vs. The Competition Export to ExcelMetricForte BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$75.41M$2.99B$5.61B$9.11BDividend YieldN/A2.39%5.24%4.01%P/E Ratio-0.657.5819.7619.92Price / SalesN/A292.00430.8999.65Price / CashN/A42.8637.4658.16Price / Book1.297.638.045.49Net Income-$35.48M-$55.05M$3.18B$250.27M7 Day Performance-23.61%8.54%3.72%4.78%1 Month Performance-16.27%5.38%3.72%7.20%1 Year PerformanceN/A2.35%29.92%17.27% Forte Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FBRXForte Biosciences3.5531 of 5 stars$10.55-7.9%$61.00+478.2%+56,027.5%$75.41MN/A-0.655Positive NewsOptions VolumeGap DownCTORCitius Oncology0.4256 of 5 stars$4.35-3.3%$3.00-31.0%N/A$321.99MN/A0.00N/ANews CoverageGap DownOLMAOlema Pharmaceuticals2.4332 of 5 stars$4.26-7.8%$24.50+475.1%-58.2%$316.11MN/A-2.1270AURAAura Biosciences2.6656 of 5 stars$6.26-0.3%$22.00+251.4%-8.6%$315.69MN/A-3.2950Positive NewsATXSAstria Therapeutics1.7589 of 5 stars$5.36-3.8%$30.00+459.7%-36.0%$314.34MN/A-2.8730ZYBTZhengye BiotechnologyN/A$5.97-9.7%N/AN/A$311.77MN/A0.00278Positive NewsLockup ExpirationGap DownLFCRLifecore Biomedical1.1732 of 5 stars$8.12-0.9%$8.00-1.5%+79.2%$303.24M$128.26M-5.60690Positive NewsHigh Trading VolumeBNTCBenitec Biopharma1.8418 of 5 stars$11.70+3.1%$23.83+103.7%+44.4%$297.94M$80K-7.7520High Trading VolumeAVIRAtea Pharmaceuticals2.7485 of 5 stars$3.60+4.3%$6.00+66.7%+19.2%$295.25MN/A-2.1870News CoverageHigh Trading VolumeIVAInventiva3.1914 of 5 stars$3.19+4.6%$10.40+226.0%+30.1%$291.77M$9.95M0.00100News CoverageGap UpAARDAardvark TherapeuticsN/A$13.52+1.0%$33.00+144.1%N/A$290.51MN/A0.0018 Related Companies and Tools Related Companies CTOR Competitors OLMA Competitors AURA Competitors ATXS Competitors ZYBT Competitors LFCR Competitors BNTC Competitors AVIR Competitors IVA Competitors AARD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FBRX) was last updated on 7/11/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Forte Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Forte Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
